My read from the last line of the announcement is that the pivotal trial is in ARDS
Sure - they regurgitated a whole heap of previously announced ad hoc analysis from the Covid trial - but my read is a pivotal study on ARDS with perhaps a separate over & under 65 cohorts.
Happy to be corrected
Ann: Remestemcel-L Survival Outcomes in COVID-19 ARDS Patients, page-24
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
91.5¢ |
Change
-0.055(5.67%) |
Mkt cap ! $1.073B | |||
| Open | High | Low | Value | Volume |
| 95.0¢ | 95.0¢ | 90.5¢ | $4.853M | 5.237M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 66808 | 91.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 91.5¢ | 117909 | 19 |
View Market Depth
| Last trade - 12.57pm 05/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |